Nasdaq:NDRA
ENDRA Life Sciences Inc.
A biotech firm advancing neurological therapeutics with a focus on innovative drug discovery platforms.
Key Metrics
Investment Thesis
Bull Case
Investors may support the stock based on the potential for a breakthrough therapy in the lucrative neurological market if clinical trials succeed. The company's strategic focus on high-value targets offers significant upside if it secures major licensing deals or achieves regulatory approval for its lead candidates.
Bear Case
The lack of current revenue and a retained earnings deficit of over $103M create substantial financial pressure that could lead to insolvency without successful financing. Heavy capital expenditures and negative operating cash flow suggest the company is burning through its limited cash reserves rapidly, increasing the risk of dilution or failure.
About ENDRA Life Sciences Inc.
Endra Life Sciences Inc. is a biotechnology company focused on developing novel therapeutic candidates for neurological disorders and other serious conditions. The company leverages its proprietary research platforms to advance drug discovery pipelines aimed at addressing significant unmet medical needs in the neuroscience sector.
Analysis
Management Discussion
The company reported a net loss of $11.5M in 2024 compared to a profit of $13.2M in 2022, indicating substantial volatility and operational challenges typical of early-stage development. Cash flow from operations was negative at $7.4M, driven by heavy research and development expenditures totaling $3.2M and general administrative costs of $7.1M.
Industry Overview
The biotechnology industry for neurological disorders is characterized by high R&D costs, long development timelines, and significant regulatory hurdles before products reach market. Success in this sector often requires substantial capital investment and a proven track record of bringing novel mechanisms to clinical success.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of Revenue | $0 | $0 |
| Gross Profit | $0 | $0 |
| Operating Expenses | $13.2M | $10.8M |
| Operating Income | $-13.2M | $-10.8M |
| R&D | $6.6M | $3.2M |
| G&A | $5.2M | $7.1M |
| Marketing | $1.4M | $571.0K |
| Stock-Based Comp | $1.2M | $571.9K |
| D&A | $96.7K | $46.5K |
| Depreciation | $96.7K | $46.5K |
| Other OpEx | $0 | $0 |
| Non-Operating Income | $-21.5K | $-690.8K |
| Pre-Tax Income | $-13.2M | $-11.5M |
| Income Tax | $0 | $0 |
| Continuing Ops | $-13.2M | $-11.5M |
| Discontinued Ops | $26.4M | $0 |
| Net Income | $13.2M | $-11.5M |
| Minority Interest | $0 | $0 |
| Net to Common | $13.2M | $-11.5M |
| Metric | 2022 | 2024 |
|---|---|---|
| Current Assets | $8.5M | $3.4M |
| Inventory | $2.6M | $0 |
| Other Current Assets | $5.9M | $3.4M |
| Long-Term Assets | $747.5K | $1.0M |
| PP&E (Net) | $235.7K | $69.3K |
| Operating Leases | $505.8K | $578.0K |
| Other LT Assets | $6.0K | $371.4K |
| Total Assets | $9.3M | $4.5M |
| Current Liabilities | $1.7M | $605.2K |
| Accounts Payable | $614.0K | $269.7K |
| Current Leases | $152.2K | $96.9K |
| Other Current Liab | $937.5K | $238.6K |
| Long-Term Liabilities | $365.9K | $1.3M |
| LT Operating Leases | $365.9K | $487.5K |
| Other LT Liab | $0 | $799.3K |
| Total Liabilities | $2.1M | $1.9M |
| Shareholders' Equity | $7.2M | $2.6M |
| Paid-In Capital | $89.1M | $106.0M |
| Retained Earnings | $-81.9M | $-103.4M |
| Total L&E | $9.3M | $4.5M |
| Metric | 2022 | 2024 |
|---|---|---|
| Net Income (CFO) | $13.2M | $-11.5M |
| Non-Cash Adjustments | $-26.9M | $5.0M |
| Working Capital Changes | $984.3K | $-849.2K |
| Cash from Operations | $-12.8M | $-7.4M |
| Capital Expenditures | $202.6K | $16.0K |
| Cash from Investing | $-202.6K | $-12.8K |
| Cash from Financing | $8.4M | $7.8M |
| FX Effect | $0 | $-1 |
| Net Change in Cash | $-4.6M | $395.6K |
| Beginning Cash | $9.5M | $2.8M |
| Ending Cash | $4.9M | $3.2M |
Frequently Asked Questions
How does ENDRA Life Sciences Inc. make money?
The company's operations are primarily segmented into early-stage drug discovery and development of novel therapeutics, clinical trial execution for neurological indications, and strategic licensing partnerships to advance its pipeline candidates.
What are the main risks for NDRA?
Significant cash burn with no current revenue stream leading to reliance on equity financing, limited clinical trial success rates typical of early-stage biotech, and potential dilution from share issuances to fund operations.
What is NDRA's competitive advantage?
Access to proprietary biological targets and unique intellectual property in the neuroscience space, a specialized team with deep expertise in translational research, and the potential for high-value milestone payments from external collaborators.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.